Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Stern

Showing results (41-50 of 90) with videos related to

Pageof 9
Sort By:
The Journal of General Virology|November 24, 1999
Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parametersClaire S Brady, Margaret F Duggan-Keen, Judith A Davidson, et al.
Human Gene Therapy|February 4, 2006
Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapyKatie L Green, Tom D Southgate, Kate Mulryan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumorsHui-Rong Jiang, David E Gilham, Kate Mulryan, et al.
Targeted Oncology|July 24, 2019
Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian CancerY Louise Wan, Puja Sapra, James Bolton, et al.
Experimental Cell Research|September 4, 2007
Novel vectors for homologous recombination strategies in mouse embryonic stem cells: an ES cell line expressing EGFP under control of the 5T4 promoterFlor M Perez-Campo, Helen L Spencer, Rhoderick H Elder, et al.
Haematologica|March 26, 2017
Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemiaOwen J McGinn, Shekhar Krishnan, Jean-Pierre Bourquin, et al.
Cancer Research|December 6, 2006
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus speciesRatish Gambhira, Patti E Gravitt, Ioannis Bossis, et al.
Biochemical and Biophysical Research Communications|January 19, 2002
5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasisAbida Awan, Melinda R Lucic, David M Shaw, et al.
Oncotarget|January 26, 2017
Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognosticKenneth Oguejiofor, Henry Galletta-Williams, Simon J Dovedi, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2007
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survivalRichard W Griffiths, Eyad Elkord, David E Gilham, et al.
Pageof 9

Showing results (41-50 of 90) with videos related to

Sort By:
Pageof 9
The Journal of General Virology|November 24, 1999
Human papillomavirus type 16 E6 variants in cervical carcinoma: relationship to host genetic factors and clinical parametersClaire S Brady, Margaret F Duggan-Keen, Judith A Davidson, et al.
Human Gene Therapy|February 4, 2006
Diffusible VP22-E2 protein kills bystander cells and offers a route for cervical cancer gene therapyKatie L Green, Tom D Southgate, Kate Mulryan, et al.
Journal of Immunology (Baltimore, Md. : 1950)|September 20, 2006
Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumorsHui-Rong Jiang, David E Gilham, Kate Mulryan, et al.
Targeted Oncology|July 24, 2019
Combination Treatment with an Antibody-Drug Conjugate (A1mcMMAF) Targeting the Oncofetal Glycoprotein 5T4 and Carboplatin Improves Survival in a Xenograft Model of Ovarian CancerY Louise Wan, Puja Sapra, James Bolton, et al.
Experimental Cell Research|September 4, 2007
Novel vectors for homologous recombination strategies in mouse embryonic stem cells: an ES cell line expressing EGFP under control of the 5T4 promoterFlor M Perez-Campo, Helen L Spencer, Rhoderick H Elder, et al.
Haematologica|March 26, 2017
Targeting the 5T4 oncofetal glycoprotein with an antibody drug conjugate (A1mcMMAF) improves survival in patient-derived xenograft models of acute lymphoblastic leukemiaOwen J McGinn, Shekhar Krishnan, Jean-Pierre Bourquin, et al.
Cancer Research|December 6, 2006
Vaccination of healthy volunteers with human papillomavirus type 16 L2E7E6 fusion protein induces serum antibody that neutralizes across papillomavirus speciesRatish Gambhira, Patti E Gravitt, Ioannis Bossis, et al.
Biochemical and Biophysical Research Communications|January 19, 2002
5T4 interacts with TIP-2/GIPC, a PDZ protein, with implications for metastasisAbida Awan, Melinda R Lucic, David M Shaw, et al.
Oncotarget|January 26, 2017
Distinct patterns of infiltrating CD8+ T cells in HPV+ and CD68 macrophages in HPV- oropharyngeal squamous cell carcinomas are associated with better clinical outcome but PD-L1 expression is not prognosticKenneth Oguejiofor, Henry Galletta-Williams, Simon J Dovedi, et al.
Cancer Immunology, Immunotherapy : CII|May 10, 2007
Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survivalRichard W Griffiths, Eyad Elkord, David E Gilham, et al.
Pageof 9